Pharmaceutical composition for elimination of cancer stem cells
A pharmaceutical composition, cancer stem cell technology, applied in the direction of drug combination, pharmaceutical formula, medical preparations containing active ingredients, etc.
Inactive Publication Date: 2014-10-22
黄奇英
View PDF2 Cites 2 Cited by
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
So far, once EGFR-TKI resistance and transfer occur, there is no effective means to prevent it
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View moreImage
Smart Image Click on the blue labels to locate them in the text.
Smart ImageViewing Examples
Examples
Experimental program
Comparison scheme
Effect test
example
[0049] 1. Materials and methods
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More PUM
Login to View More
Abstract
The preset invention relates to use of antipsychotic phenothiazine derivative for eliminating cancer stem cells (CSCs) and / or preventing a cancer. The invention also provides a pharmaceutical composition for treating a cancer, and / or preventing or delaying cancer recurrence comprising trifluoperazine and an anti-cancer drug, such as gefitinib or cisplatin.
Description
technical field [0001] The invention relates to a pharmaceutical composition for eliminating cancer stem cells. Background technique [0002] Recently, the cancer stem cell (CSC) hypothesis has attracted much attention. CSCs possess stem cell properties, including self-renewal, stress / drug resistance, and enhanced mobility, which lead to tumor recurrence, metastasis, and chemotherapy resistance. Putative CSCs were first identified as CD133 + / Oct4 + / Nanog + cells (Eramo A et al. Cell Death Differ2008; 15:504-514), and isolated from established non-small cell lung cancer (NSCLC) cell lines (Pirozzi G et al. PloS one2011; 6:e21548; and Leung EL et al. PloS one 2010;5:e14062). Lung CSCs may have the same functional properties as lung precursor cells, including the ability to actively exclude the Hoechst stain (Hoechst) 33342, which identified these cells as side population cells in flow cytometry ( Storms RW et al. Blood2000; 96:2125-2133), and expressed high aldehyde de...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More Application Information
Patent Timeline
Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/5415A61P35/00A61P35/04A61K33/243
CPCA61K31/5415A61N5/10A61K31/5377A61K33/24A61K31/4706A61K45/06A61P11/00A61P35/00A61P35/04A61P43/00A61K33/243A61K2300/00
Inventor 黄奇英
Owner 黄奇英
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com